TM
NRIX icon

Torren Management’s Nurix Therapeutics NRIX Stock Holding History

Torren Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43K Hold
59
– – ﹤0.01% 661
2026
Q1 		$915 Hold
59
– – ﹤0.01% 756
2025
Q4 		$1.12K Buy
+59
New +$848 ﹤0.01% 1178

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $587M AUM 20.13% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Torren Management's NRIX Position: Q2 2026 in Review

Torren Management held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 59 shares worth $1.43K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

Torren Management first reported a position in NRIX in Q4 2025 and has held it in 3 quarters since. 64 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Torren Management held 59 shares of Nurix Therapeutics worth $1.43K as of Q2 2026.
  • Torren Management left its Nurix Therapeutics share count unchanged in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #661 holding.
  • Torren Management first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 64 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.